Author:
Chrzanowski Wlodzimierz K.,Marcus Ronald N.,Torbeyns Anne,Nyilas Margaretta,McQuade Robert D.
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. APA (1997) Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry 154:1–63
2. Cornblatt B, Kern RS, Carson WH, Ali MW, Luo X, Green M (2002) Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. Int J Neuropsychopharmacol 5(Suppl 1):S185
3. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V (1999) Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 100:1481–1492
4. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763–771
5. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003) Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6:325–337
Cited by
122 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献